Joel Isaacson & Co. LLC Increases Stock Position in Pfizer Inc. (NYSE:PFE)

Joel Isaacson & Co. LLC increased its stake in shares of Pfizer Inc. (NYSE:PFE) by 7.8% in the 4th quarter, Holdings Channel reports. The firm owned 83,673 shares of the biopharmaceutical company’s stock after buying an additional 6,028 shares during the period. Joel Isaacson & Co. LLC’s holdings in Pfizer were worth $2,220,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. Retirement Wealth Solutions LLC bought a new position in Pfizer in the fourth quarter valued at about $26,000. Gladius Capital Management LP grew its position in Pfizer by 102.8% during the third quarter. Gladius Capital Management LP now owns 1,043 shares of the biopharmaceutical company’s stock valued at $30,000 after buying an additional 38,015 shares during the period. Teachers Insurance & Annuity Association of America bought a new position in Pfizer in the third quarter worth approximately $35,000. Joseph Group Capital Management boosted its stake in shares of Pfizer by 168.3% during the 3rd quarter. Joseph Group Capital Management now owns 1,229 shares of the biopharmaceutical company’s stock worth $36,000 after acquiring an additional 771 shares during the last quarter. Finally, Sugar Maple Asset Management LLC purchased a new stake in shares of Pfizer in the 4th quarter worth $43,000. Institutional investors own 68.36% of the company’s stock.

Pfizer Stock Performance

NYSE PFE opened at $25.76 on Friday. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.73 and a current ratio of 1.00. The business’s 50 day moving average price is $26.29 and its 200-day moving average price is $27.77. The company has a market cap of $145.96 billion, a P/E ratio of 18.27, a P/E/G ratio of 0.64 and a beta of 0.64. Pfizer Inc. has a fifty-two week low of $24.48 and a fifty-two week high of $31.54.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, topping analysts’ consensus estimates of $0.48 by $0.15. The firm had revenue of $17.76 billion during the quarter, compared to analysts’ expectations of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The firm’s revenue for the quarter was up 24.7% compared to the same quarter last year. During the same period in the previous year, the company earned $0.10 EPS. Sell-side analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.

Pfizer Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 7th. Shareholders of record on Friday, January 24th will be paid a $0.43 dividend. This is a positive change from Pfizer’s previous quarterly dividend of $0.42. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a yield of 6.68%. Pfizer’s dividend payout ratio (DPR) is presently 121.99%.

Wall Street Analyst Weigh In

Several equities research analysts recently issued reports on the stock. Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. Citigroup cut their price target on Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research note on Tuesday, January 28th. UBS Group dropped their price objective on Pfizer from $31.00 to $29.00 and set a “neutral” rating for the company in a research note on Wednesday, January 8th. Bank of America reissued a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a report on Tuesday, December 10th. Finally, StockNews.com lowered shares of Pfizer from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have assigned a strong buy rating to the company’s stock. According to MarketBeat.com, Pfizer has a consensus rating of “Moderate Buy” and an average target price of $31.92.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.